Page 76 - Predicting survival in patients with spinal bone metastasesL

CHAPTER V
Table 1. Patient characteristics. SD: standard deviation.
Gender Female Male
Age (mean, years ± SD)
Location treated spinal metastases
Cervical only Cervicothoracic Thoracic only Thoracolumbar Lumbar only Diffuse
Visceral and/or brain metastases Present
Not present
Karnofsky performance status Normal (100-80%) Impaired (70-10%)
Missing
Initial SBM treatment Radiotherapy Surgery
Systemic / Palliative
Molecular phenotype Luminal A Luminal B
HER2
Triple negative
110 (99) 1 (1) 59.9 ± 13.9
None 12 (11) 34 (31) 25 (22) 17 (15) 23 (21)
56 (50) 55 (50)
58 (52) 52 (47) 1 (1)
69 (62) 21 (19) 21 (19)
67 (60) 9 (8) 11 (10) 24 (22)
Characteristic
N (%)
Table 2. Survival data per hospital and phenotype. MOS: median overall survival. P-values refer to overall log-rank comparison.
Variable
N (%)
MOS (95%CI)
p-value
Hospital Leiden Graz Aarhus
Molecular phenotype Luminal A Luminal B
HER2
Triple negative Receptor Status
Receptor positive Triple negative
61 (55) 39 (35) 11 (10)
67 (60) 9 (8) 11 (10) 24 (22)
87 (78) 24 (22)
18.0 (9.5-26.4) 16.6 (8.8-24.4) 14.7 (3.1-26.4)
22.5 (17.9-27.0) 26.9 (9.1-44.7) 20.9 (1.1-40.8) 5.5 (2.0-9.0)
23.4 (19.0-27.8) 5.5 (2.0-9.0)
0.529 <0.001
<0.001
The subsequent survival analysis showed a median survival time of 23.4 months (95%CI 19.0-27.8) for the receptor positive category and 5.5 months (95%CI 2.0-9.0) for the triple negative category (p<0.001) (figure 1B and table 2). The corresponding hazard ratio was 3.6 (95%CI 2.1-5.9, p<0.001). The median time to development of symptomatic SBM from diagnosis of the primary tumor was 11.0
74